Nasdaq

Assembly Biosciences Reports Promising Interim Results for ABI-4334 in Phase 1b Study for Chronic Hepatitis B Virus Infection

ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
Benzinga.com

Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)

Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...
Nasdaq

Assembly Biosciences Initiates Phase 1a Study Of ABI-6250, Oral Entry Inhibitor For

(RTTNews) - Assembly Biosciences (ASMB), a biotechnology company focused on developing treatments for viral diseases, announced on Wednesday that the first participant has been dosed in its Phase 1a ...
Morningstar

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral ...

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...